Sebastian Ochsenreither

Charité - Universitätsmedizin Berlin

Research Interests

Explore related searches

Articles (14)

Collaborators (3)

Anja Williams

Scripps Research Institute

UNITED KINGDOM

Frederick Klauschen

Professor, Chair

Ludwig-Maximilians-Universität München

Ulrich Keller

Charité - Universitätsmedizin Berlin

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sebastian Ochsenreither

Research Interests

Explore related searches

Articles (14)

Collaborators (3)

Anja Williams

Frederick Klauschen

Ulrich Keller

Make your next move.

Sebastian Ochsenreither

Research Interests

Explore related searches

Articles (14)

Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis.

Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study

Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer

Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of CheckMate 627, an Adaptive Basket Design Clinical Trial

Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens

A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma

Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study

Comprehensive analysis of the tumor immune microenvironment (TIM) in advanced adenoid cystic (ACC) and non-adenoid cystic salivary gland cancers (SGC)

Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG)

Precision oncology for resistant acral, mucosal and cutaneous melanomas: A prospective broad high throughput genomics feasibility study

Proteogenomic analysis reveals RNA as an important source for tumor-agnostic neoantigen identification correlating with T-cell infiltration

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors (vol 7, 100447, 2022)

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow

Collaborators (3)

Anja Williams

Frederick Klauschen

Ulrich Keller

Make your next move.